Few years ago, multinational pharma companies seeking growth and respite from market uncertainty in Europe and the United States found a haven in emerging markets. However, a more somber outlook soon replaced early euphoria. Some emerging markets either suffered downturns or showed weaker growth forecasts as commodity prices fell; some healthcare systems struggled to scale up adequately their provision of care; and local companies became increasingly effective competitors in the pharma market. Furthermore, multinationals themselves often found it difficult to scale up in emerging markets, with particular challenges in talent recruitment, compliance, and organizational setup.
To capture opportunities for growth in these markets, multinationals must be prepared to take a long-term view, continue investing in emerging markets, and take calculated risks (more info on the post "overcome the distance").
To succeed in this and move on from the old “go and grow” mind-set, they need to build an agile organization tailored to emerging-market.
Build an agile Lyophilization Production
In the wake of blockbuster drugs going off patent, large pharmaceutical companies are turning to biologics and vaccines for a steady revenue stream. Innovation in the vaccines industry is increasing rapidly to target diseases that were previously not considered attractive.
This means, aseptic processing of large-scale lyophilized injectables, and the challenges and demands to overcome in this technology!
To meet increasing cGMP expectations, especially how to control personnel contamination – the greatest challenge in aseptic critical process
To keep cost competitiveness and production efficiency as well
Faster time to market
